Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

The Cancer Secrets Podcast

The Cancer Secrets Podcast artwork

CSP S7EO95 - Ep.95, Advancing Cancer Screening: A Conversation with Dr. Tarek Mouhieddine of POM Health

May 20, 202648 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this insightful episode of the Cancer Secrets podcast, Dr. Jonathan Stegall welcomes special guest Dr. Tarek Mouhieddine, an oncologist and physician scientist, to explore the evolving landscape of cancer screening and prevention. They discuss why traditional cancer screening guidelines are outdated and highlight the persistent blind spots in standard care, particularly the gaps in screening for less common yet impactful cancers. Dr. Tarek sheds light on the limitations and discomforts of current screening methods, such as colonoscopies and mammograms, and underscores the urgent need for more accessible, evidence-based approaches. The conversation pivots to Dr. Mouhieddine's work as co-founder of POM Health, an innovative platform designed to provide comprehensive, oncologist-led cancer screenings using cutting-edge blood, urine, and imaging tests. Together, they discuss the emotional dimensions of cancer anxiety, the transformative potential of early detection, and how emerging technologies like the Galleri test can detect multiple cancers earlier than ever before. Listeners are also guided through the practical steps for accessing Palm Health's services and the hope for broader, insurance-covered access in the future. Ready to stay ahead in cancer prevention and gain true peace of mind? Listen now, subscribe for more expert insights from the Cancer Secrets podcast, and share this episode with anyone who cares about proactive health!

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

Hi and welcome to the Cancer Secrets podcast. I am your Host and guide, Dr. Jonathan Stegall. Cancer is like a thief who has come to steal, kill and destroy. I have personally seen it wreak its havoc on patients, friends, and even my own family. But I am on a mission to change the cancer paradigm through the practice of integrative oncology cancer treatment that integrates the best of conventional medicine with the best of alternative therapies. Backed by science and personalized to each patient. You need a positive voice you can trust. This podcast will share valuable

information to give you practical hope for a better outcome. So I invite you to join me on this journey as we seek to change the cancer paradigm together. Well, hello and welcome back to the Cancer Secrets podcast. I'm your host, Dr. Jonathan Stegall, and this is season seven and episode number 95. And today we have a very special guest. Joining us is Dr. Tarek Mouhieddine. How are you, doctor? I'm doing great and thank you so much for having me today. I really appreciate it and very excited to talk together about what we're doing. Yeah,

excited to have you. I'd love to introduce you to our listeners. But just so everyone knows, Dr. Mouhieddine is a medical doctor. He's a physician scientist. He's a clinical investigator whose research focuses on improving cancer treatment outcomes. He has a strong background in lab based and translational research with expertise in tumor genomics and the immune microenvironment. Dr. Mouhieddine is passionate about advancing precision cancer care in early detection and interpretation of blood cancers and translating laboratory discoveries into first in human phase 1 clinical

trials in multiple myeloma. He completed medical school at the American University of Beirut and completed his internal medicine residency and hematology oncology fellowship at at the Icahn School of Medicine at Mount Sinai Hospital. He is currently on faculty at the Dana Farber Cancer Institute in Boston. He is also the co founder for Palm Health, an oncologist led cancer screening service that gives people access to more comprehensive cancer screening tests. Doctor, welcome again. Thank you. Thank you so much for having me. So I'm really excited to have you here today, not only because you're an oncologist who

works in the field, but also someone who's passionate about cancer prevention. So if we could start out, I would just love to know more about what drew you to oncology as a career choice. Yeah, honestly, I think I would say it started when I was a kid, honestly. And it wasn't specifically oncology, at least when I was a child, but it was science I was a very nerdy kid at school. I loved science a lot. I was the one who would always stay back in class and just want to talk more and more with a teacher about things

and, like, always wanted to do more experiments. So part of that was looking more into oncology and cancer. And, you know, of course, all the fields in medicine are driven by research, but I would say oncology is one of the fields that are extremely driven by research. And as an oncologist, honestly, even if you're working full time clinical, you have to have a little bit of some research or scientific background, because a lot

of the things that we do has or needs at least some scientific or background to fully understand what's going on. And I would say, as I grew up, basically, I started being drawn slowly into the medical field in terms of interest. And I felt that in oncology I could see patients, treat them, help them, but at the same time, I could still keep that research passion going and be able to do two things from that aspect. And out of all the fields in medicine, I would say

oncology also interested me the most compared to, let's say, cardiology or gi, because I felt that in oncology you can help a lot of people and really change their lives significantly. And it's usually, or in a lot of cases, at least a matter of life and death. And you can basically take someone from end of life to actually having decades again and living their life to the fullest and seeing their kids grow up, seeing their grandkids, and

being part of that journey actually is very, very rewarding and something that I enjoy doing every day. I love that. And you clearly have a real heart for it, and that's. That's great. We need more doctors like you. Thank you. Thank you. So I'd like to talk about cancer screening in today's episode. And, you know, you and I have talked about the fact that most Americans believe they're being screened for cancer, but. But they're really not. And, you know, you said that the current, you know, standard of care for screening has a massive blind spot. So how did

that gap form? Yeah. No. So I don't know if, you know, but the current standard of cancer screening or the recommendations that we have these days are actually decades old. They're not updated. Except until recently, just the colon cancer screening guidelines got upgraded. Exactly. But otherwise, when it comes to breast cancer, lung cancer, cervical cancer, and prostate cancer, at least those have been the same for so long, specifically breast

cancer. And so the reasoning behind it, I guess I would Say it's. First of all, it's because they're very common cancers, so very easy to see all the time. And of course, it was much easier at least decades ago to screen for them and intercept and do large clinical trials to actually prove that screening for those cancers improves outcomes. When we go to other cancers which are less common, it becomes definitely much harder to actually run those big trials and prove that screening ahead of time actually

improves outcomes. And then again, the technologies or the ways to screen were definitely different before compared to now. So now we're getting better and better at screening, and we're even becoming less invasive when it comes to screening. And I guess now that the world is changing and we have better tools and instruments to do that, I think now is the best time to start thinking about those other cancers that didn't really get the attention they needed. Because, you know,

okay, breast cancer and lung cancer are top common cancers. But then that doesn't mean gastric cancer and bladder cancer are less important. There are tens of thousands of people in the US Alone with these cancers. And of course, they deserve to be screened as well for those cancers, just as well as people who are being screened for breast and colon. And so I think the intent to screen and help people, of course, is there. The problem is that we didn't have the tools before and we didn't have the resources. And usually it's a matter of balance between how many

people out there actually will have that cancer, how much can the healthcare system actually do in terms of providing and spending, in terms of screening. And all of these things come into play. Unfortunately, sometimes, or the way the system works is there are some compromises that are made because the health care system in general is not able to accommodate everybody. Right, right. Well said. So let's talk about sort of the standard of care for cancer screening, if you will. We kind of touched

on them, but we have colonoscopies for colon cancer. We have mammograms for breast cancer. We have, you know, Pap smears for cervical cancer, you know, rectal exam and PSA for prostate cancer. You got to talk a little bit about those. And sort of. Sort of maybe what? How. Just let's just assume people aren't familiar with maybe with screening. Let's. Let's have a. Take a. Listen. Who hasn't really thought much about screening? What does that look like? And then what are some of the limitations you would say are with each of those methods? Yeah, no, of course. So, you know, at least for colorectal cancer, as

well as breast cancer, we have, as people know, colonoscopies and mammograms, But I would say at least colonoscopies, even more. They're also invasive. So first of all, you have the limitation of when you can do this. So the recommendation for colonoscopies used to be 50 years old, and then they recently brought it down to 45 years old. And that is mostly driven by the fact that we're seeing more and more cancers, unfortunately. And by bringing the age lower to 45, we're able

to catch people at much earlier stages rather than getting them diagnosed at stage four, which is in the incurable stage. So the first barrier is when you can start screening, and the second one is, for example, colonoscopies. You would need to go. You would need to get anesthesia, basically, you will have. You will need a tube going into the colon and with that. Exactly. And do the prep, which is the most annoying part for people. And, you know, first of all,

actually, the amount or the number of slots that are available to do that, that's actually a big limitation. So how many times can you do colonoscopies per day? And how many clinics actually are available to accommodate all those people? So if you just try and get a. So let's say you're eligible, just trying to get an appointment for colonoscopies. Just see how long the wait is. Usually it could be, depending where you are in the country, of course, it could be weeks to months before you can get a slot. And then even with

that, of course, being under and going through the colonoscopy itself has risks. So there's risks with anesthesia, there's risks with the actual procedure, like causing bleeding, causing perforation in the bowel. So it's not safe, like 100% safe. There's always risks that could happen. And of course, when it comes to, let's say, breast cancer with mammograms, it's definitely not as invasive. But it also comes with some downsides. So, for example. So, of course, when I talk to patients that I have who've underwent mammograms, I

rarely have patient who tells me it was pain free. They always tell me, oh, it's so painful when they have to go through the mammogram because it has so much pressure on compression tissue. Exactly. So it's an uncomfortable experience. It's not a dangerous experience, but it's still uncomfortable. And then you also have the fact that it's radiation exposure. You also have that. And on top of that similar to colonoscopies, you also have the age limit or when you can start using that and being covered, basically. So it's usually age 40 if you

don't have any risk factors or like the BRCA gene or family. Strong family history. And so the problem is that even with those ages being the starting ages, I still, or I'm sure you have to seen patients who are in their 20s and 30s who come in with breast cancer and colon cancer specifically these days, and they're sometimes at very advanced stages. So the current screening methods are good. They can definitely detect. They are saving people and saving lives and helping people discover things early.

But they're not perfect, they're not fully safe, and they're not fully convenient. Going into pap smears as well, it's a similar situation. It's uncomfortable, it's a little bit invasive, and, you know, right now, it. It does the trick. But at the same time, it's not similar to the other situations. You have to find an appointment. You have to go through this invasive, uncomfortable procedure. For prostate cancer, I would say it's probably the most convenient and easiest one when it comes to, like, PSA checking in the blood. And the hope is that most

of these cancers can be screened in that manner. Of course, digital rectal exam is part of it. But if we can get to a stage where. Or a phase in life where everything can be screened for very easily without being too invasive, like a blood test, like the PSA for prostate cancer, that would be the most ideal situation. And that's what we're aiming for here. Right, Right. I love that. And I would agree. I mean, the methods we have aren't bad. They're just incomplete. Right. They need to be better. Exactly. They. Those tests themselves could be improved upon, I think. And then, not to mention all

the cancers that they don't test for. Right. I mean, we talk about cancer as an umbrella term for over a hundred hundreds of different actual diseases that are under that cancer umbrella. That's a lot. We're not testing with our usual methods. Yeah, exactly. Typically don't get detected unless someone's having a. A chronic symptom of some sort. Yep, so. Exactly. And like, even mammograms, like, when we do them, like you said, they're great, and they can definitely detect things. But there are patients who have, for example, very dense tissues, and it actually doesn't help at all. You. You

can't rely on a mammogram to really detect it. And actually, there are studies now to show that if you go back in time and look at all the mammograms that were supposedly negative and now you're using actually AI to look into those images, they are actually able to define specific very tiny areas that were always missed before and they were always called normal. And now they're calling it, oh, there was something there that should have been caught. And so, you know, what we have right now is good, but it's not perfect like you said. And there's always room for improvement.

Dr. Mouhieddine, you're bringing up another point in my mind that, you know, let's also talk about false positives, right. Of how many times do, do patients have a test, especially mammogram, it says, oh, this is suspicious. The woman has, you know, a lot of anxiety around that she has to go back in. Does she have to have another test? Does she have to have a, an invasive biopsy? It turns out to be nothing. Right. And that happens a lot more than we like to think about and talk about. So. Yeah, no, that happens very frequently, unfortunately. And that just goes to say that our tests, I don't want to say they're bad,

but they're not perfect because they can call false positives. And even worse, I, I would pick having a false positive over a false negative. Right. And that's the more dangerous side where they would say, oh, there's nothing there, while there actually is an early cancer that we're not able to call yet. Right, exactly. So that, that sort of is a nice segue too, into another thought I had of just this whole idea of cancer anxiety. I mean, we, you know, we obviously patients who have a cancer diagnosis

have a certain degree of anxiety around, you know, what does this mean for me? And you know, we talk about the term scanxiety. They have to go get another scan. Is it going to be normal? Is it going to be abnormal? But we don't talk enough, in my opinion, about, about the cancer anxiety sort of epidemic in non cancer patients. Right. I mean, we all know someone who's, who's had cancer or gone through cancer and you know, that naturally creates a certain level of anxiety within us. Well, what about me? Do I have cancer? Do I need to worry about?

So can you talk a little about what sort of peace of mind looks like around that and how we can do better on that? Yeah, no, of course. And honestly, and I think you probably also went through that, at least I remember throughout medical school, every time I learned about new things, I would leave the session saying, oh, I definitely have that disease. Because when you know more and see more around you, you just start trying to connect the dots, like you have a few symptoms and you say, oh, what if I have this? Or what if I have that? Absolutely right. And so

I think because of that I feel, and I mean, back then I was a medical student and, you know, I didn't know as much and I was still in the learning process. And I feel the reason why I'm not like that anymore is because I have more knowledge and I have better expectations about things and like, experience made things better. And this is how Palm Health can help. And you know, as a patient who usually, or a person who's not sick, fully healthy, and maybe doesn't have a medical background, they would of course see

cancer being on the rise. For example, have a few family members or friends with cancer, and they start thinking to themselves, what if it's me? What if it was me? And, you know, not knowing much about the cancer risk and what to look for is a major driver of this concern and anxiety, I think. And that's why I'm bringing up myself as an example when I was a student versus now, where, because I know more and I know what to think about and what to look for my anxiety, or I would say I wouldn't have that. I don't have

that anxiety anymore. And so where Palm Health helps and why we created this way, we wanted it to be oncologist led. And that basically means that everybody who connects with us has an oncologist in one way or another. And so the way the system works right now is that when you don't have a diagnosis of cancer, you cannot see an oncologist. Usually when you see an oncologist, you have to come in with that

diagnosis. Right. And so people will ask their primary care physician who would be amazing and great at what they do, but they don't see cancer every day, and it's not part of their learning process and experience. So they might not have all the answers that would address people's anxieties compared to if you actually don't have a cancer diagnosis, but you have access to talk to an oncologist, bring up your worries, talk about why you think you might

have cancer or what's worrying you, and then you have someone who has that background that actually can guide you through it and tell you if you really should be worried or that you're just a very, very, very low risk person to develop cancer. I think that's one of the positive things about Palm Health. So it's not just about testing and screening, but it's about actually having someone you can bring up these points to and discuss things and hopefully give you a peace of mind when it comes to really your

cancer risk. And I think that is the highlight of this platform, even more than the actual screening itself. Because a lot of people that I've already spoken to right now so far through Palm Health actually start feeling better just through that visit alone and even before we test for anything. And I think a lot of the worry that they bring in is I definitely never dismiss any worry or anxiety because I understand where they're coming from. But at least when they bring it up, I am able to address it and tell them that you actually shouldn't be worried

that much or in a few cases, I guess. Okay, yeah, I think, yeah, we definitely need to investigate this and do the next step. So I think that's a great factor that helps people. Well. And Palm is actually an acronym for peace of mind, right? Yeah, exactly. The name. Palm Health. Yeah. Yeah, I love that. So you're one of the co founders of Palm Health. I mean, just tell us, tell us a little bit more about sort of what led you to start this. I mean, did you just see sort of a lack of resources out in the marketplace for this kind of thing?

Yeah. So honestly this, of course it wouldn't have been possible without the other co founders. You know, to me it was definitely an idea and it was also an idea with the other co founders with me. And I think the stars aligned and made us meet and actually discover that we all have similar idea and a similar concern about things. And from at least from my standpoint, the way or the reason why I thought about it and wanted to do something like this comes from when I was back in training for during my

oncology years of training. So of course I was younger and I was in my 20s and you know, I was seeing patients from all types of cancers. So during your training you don't focus on one specific things, you see all types of cancers and crazy. I was seeing very young people, younger than I was. Even with cancers that we normally don't see until your 50s or 60s or 70s, I was seeing those in 20

something year olds and 30 something year olds and that drove me crazy. Those patients would come in to the hospital because they're sick for with whatever symptom they have, they don't know what's going on. We admit them, we start the workup and we discover, I can't forget several of those Patients where they were 20 something year olds and we would find stage 4 metastatic colon cancer. And the crazy part about that is that they didn't even have risk factors. They didn't have a strong family history of colon cancer, they didn't get exposed to

anything that would explain this and they still got it. I'm not saying it's a huge portion of patients, but it exists. And because of that, that made me go back and think, okay, we are screening patients starting age. Usually it used to be 50 and then it went down to 45, but then I'm seeing patients with stage four cancer in their 30s and 20s. Yep. Yeah, so what, what are we going to do with that? And, and you know, the guidelines to screen for at 45 still allows you to screen younger if

you have a strong family history. So sure that that can help, but what about the people that I saw that didn't have any risk factors? They would never be eligible with the current guidelines. And so with that in mind and me seeing how the world is changing in science and me having such a nerdy interest in research and what things are being produced and generated, I started seeing different avenues or companies establishing or creating new assays

that are blood based, not so invasive. Basically, when it's a blood test that can test for a large group of different types of cancers. And that made me think that, okay, if this technology is available and it's a blood test, it's not a colonoscopy, it's not a mammogram, it's not an X ray where you're exposed to radiation, why can't we start using that? It's not going to burden the healthcare system. Right. It's because it's a blood test. It's not an appointment

for a CAT scan, it's not an appointment for a colonoscopy which will take away from other people who need it, it's just a regular blood test. You can go to any lab and do it. Why can't we start doing that for all the younger people who are not eligible to be screened with a colonoscopy or mammogram, for example, they don't have the high risk family history and see if we can start catching things early. And when I met the other co founders, they had similar thoughts before. They didn't have, for example, the experience that

I had with seeing young patients, but they are seeing the trends. They have seen that cancer is on the rise. And of course both of them have or know someone with cancer. So there's Always that experience that touches everyone. And so when we met and we discussed this, we said, why don't we create a platform where people who don't have cancer but want to be screened have the chance to actually talk to oncologists, talk about the risk, and then actually have those assays that are being now

developed and showing that they can detect cancer early be available for them. So that's how it started. I love that. That's a great story. What a. What a great. What a great venture. I mean, we need this so badly. Yeah. Like you, I've seen so many. So many young patients with just these sad stories of, you know, advanced cancer in their 20s and 30s, and, you know, certainly in integrative oncology and in my field, you know, we talk a lot about nutrition and environmental exposures and all these things that we're still learning more about. But, I mean, something changed, right? We're not just catching cancer better.

That's not why we're seeing more and more of it. We're not seeing it earlier. We're seeing something has changed. And if we can start catching it earlier, you know, we're going to improve outcomes. Right. Because as we talk about, you know, an ounce of prevention is worth a pound of cure. I mean, we. We. We catch a stage one or two. That's a very different conversation than a stage four. Yep. For sure. Exactly. I mean, there's no question there that catching cancer early at stage one will save lives. And, you know, it's very well documented that, you know, if you catch something at stage

four, it's. In most cancers, it's incurable. If not. I mean, I don't want to say all cancers, because there are certain cases where it's still possible, but stage four is usually incurable at that point. And if we can catch it even at stage three is better than stage four, and there's a much higher rate of cure and basically surviving. And I don't want to say that the cancer field is not improving. It's actually very impressive what we're able to do these days, even for stage four cancers. And survival has definitely doubled and tripled and

quadrupled in some cancers for stage four, because treatments have gotten better. But at the same time, for stage four, you actually, even with all the improvements, it's still not curable. And at the same time, you're still being exposed to treatments chronically all the time. You have to be on something, whether it's maintenance or several cycles of chemo before you can take a break. So there's always something that's going to keep affecting you, whether it starts causing side effects, it starts affecting your quality of life, it starts making you have to go to doctor's appointments every week,

that that impacts people a lot. And so even though outcomes have gotten way better for stage four and you can do so much better if we can prevent all of that and just catch things so early, get rid of it at stage one, let's say you would avoid having to go through all of those therapies and toxicities that can really impact how you live. Right. Well said. So I'd like to dig a little deeper in terms of Palm Health. Which test specifically does Palm Health utilize to create a

more robust cancer screening protocol? Yeah, so I mentioned earlier that there were several avenues or several companies out there that actually have built different assays that are blood based, that look for cancer, cancer signals basically. And so we looked at different ones and looked at their data and how long they've been there and if their long term follow up is actually impressive enough. And basically we compare them and the clear winner was a company gallery or Grail and their test was called, is called gallery.

And you know, they've had multiple trials right now that look into screening and if that's actually catching things early and of course we need, I would say really decades to prove overall survival benefit from the time you actually screen and catch things. But at least it's a start that it's actually catching things early. And so there are even other companies that are now coming out with their own assays. And I would say right now we are very convinced with the assay that Gallery or Grail

provides. And I tell this to everyone, we're not like focused on just one assay. We're always monitoring the changes in the field. And if in five years or 10 years there's a very new powerful assay that catches even more things or has a higher sensitivity, we're definitely going to pivot. We will always go for the best assay to catch things. But of course the gallery assay is not the only one we utilize. There are other tests, blood based tests that we

actually use as well, which normally they're used for monitoring for example, other cancers. So for example, there's CEA, there is AFP, there is CA15, 3 and CA125. So these are, for example, markers for different cancers like pancreatic, liver, breast, that we don't normally use them as screenings, but they definitely increase in the bloodstream when you have any of those cancers. And so in addition to the gallery test, we have those as part of the tests. Because,

you know, the best way to really catch something is to try as much as possible to cover all the bases. Because like we mentioned before, there's always the possibility of a false positive or a false negative. And really to prove that this is a true signal, if you have two things that are positive, so one from the traditional assays in the blood and one signal coming from the gallery test that increases the likelihood that this is a true positive. And we actually really need to look deeper into that. So these are the main things

that drive our screening platform. And so in addition to that, we do have a few other tests, one, a few that are urine based. For example, the best way to catch bladder cancer, for example, is to look for malignant, early malignant cells in the urine. Because once the bladder cancer starts forming, even at the very early stages, you can start shedding these tumor cells into the urine. And if you see them, then that should tell you or alarm you that there's something growing in the bladder. And people unfortunately don't catch bladder cancer until

much later, because at later stages you start seeing blood in the urine, for example. But when it's so early, the urine will still look fine, but you can still see these cells, maybe it could be one cell even, but you'll still catch it and then you'll know there's something wrong. And then finally there is an imaging component which can really fill the whole picture and complete the whole picture. And out of all the imaging modalities, I definitely wanted something that is not super invasive.

And what that means is lowering risk of any long term side effects. And that's why we went for magnetic based images rather than X rays. Exactly. So we went for whole body MRIs, because, you know, with CAT scans, for example, you still are exposed to radiation. It's not a dangerous level of radiation. But if we're talking about screening throughout your life, from a young age all the way until you're, let's say, 80,

if you're always exposed to radiation, and if we end up doing this every year or every few years, you're going to be exposed to so much radiation over time, and that defeats the purpose. While being in a magnetic field, it's not really dangerous. And so that's why we also partnered with Prenova, which is one of the companies that actually also even uses AI in addition to radiologists to actually look at images to be as accurate and sensitive in catching things as possible. And

that definitely will complete the picture, because not all cancers secrete things in the blood. And so if we're doing a blood test, we can catch a lot of things, but there's still a very, very small risk or possibility that whatever you have might not be secreting anything. There are cancers that don't secrete anything to begin with, and there are cancers even like breast cancer, where. Or pancreatic or colon, that can secrete their typical marker, but there would be a few cases where they don't at all. And then if we're

purely relying just on the blood, then we'll miss it. And that's where the MRI or the full body MRI comes into play to help fill that gap. This is great. I mean, this is really like the Rolls Royce of. Of cancer screening. I mean, like you said, you kind of start with your base of gallery. And. And our listeners are familiar with that because at episode 86, we talked about the gallery test on here, and I use that with. I use that with my patients. Actually, after we've. We finished treatment, you know, six, eight, 12 months down the line, everything's looking good. Sometimes I'll do a gallery just to see if it picks up anything from

what we've been treating as well as the 50 plus other types. But as you said, you know, that's. That's just a start because sometimes we need pictures too. And so the. Yeah, the full body mri. And that's a non contrast mri, correct? Yes, exactly. Yeah. Okay. And then that plus all the other testing. This is. This is awesome. So I. My understanding is with Palm Health, you have a few tiers, right? I think it's three tiers. So can you talk to us about the kind of. The tiers of testing that patients can kind of choose from? Mm, yeah. So we have three tiers, and the first two are

purely blood, urine, and there's a stool study as well. And then the third tier is the one that includes imaging, which is prnovo. The reason we created three tiers is because, unfortunately, because all of these are still. Or at least the gallery test is still not FDA approved and covered by insurance, people will still have to. Exactly. Everything's still out of pocket. And especially if you're young and you don't have risk factors, you can't still. Right now,

at least these days, you can't make the case for your insurance company to cover that for you. So we wanted at least to get some people to be able to be screened for at least a big chunk of the cancers that we can do with different tiers of out of pocket expenses. So there's the basic plan and then that is blood based. And it basically goes for at least 60, actually 70 cancers just by looking into the blood. And

it covers definitely all the basic ones and the more common ones. So including pancreatic cancer and colon cancer, liver cancer, rather than going into the more rarer ones like sarcomas for example, where it's definitely, it can definitely happen and exists, but it is less likely to be detected or to exist in, in fully healthy people. And then the second tier adds more blood tests or assays into this. The gallery test is part of all of them. So for sure you have

that in all tiers. But then you add on top of it all those extra traditional tests that I mentioned that would really reconfirm any of the signals that we might or might not see with the gallery test. And so it basically is more blood tests to capture more cancers. And on our website actually we have a list of which cancers are covered under each tier. So we start with the basic one and then the next one is everything that the basic covers plus a list of cancers that we can, we will be able to detect with these extra

tests that we added on. And then finally, like I mentioned, the third one would be just adding the imaging component which can help in detecting cancers that are either non secretory so they don't secrete anything to begin with and those are usually rare cancers or at the same time catch things that usually secrete things like colon cancer. But still you are one of the very, very few people whose colon cancer turned out not to secrete anything which can happen rare, but

also exists. So the price range actually goes from around 1600 for the basic one, it doubles to around 3400 for the second one. And then when you add the imaging component that goes up to around 5,800. MRIs are still very expensive. But the one thing that we looked into as well is that seems like you are able to pay for all this through HSA

accounts. So at least that is good start, that at least you can have those pre tax savings and use that money towards paying these. But we're hoping at some point in the future, over time and it wouldn't be just us. I think there's an interest in a lot of even academic centers to prove that screening for all those cancers actually improves outcomes, that at some point in the future all of this will be covered once we have enough data and long term outcomes that prove that using these modalities are catching more and more cancers. In younger people or people who are not at risk,

and that is leading to cures and of course, survival, better survival. Right. So either there's something there and we're catching it sooner and we're improving, you know, odds of having a good outcome, or there's nothing there and you get tremendous peace of mind that you're, you're doing everything you can to, to sort of check for cancer and nothing was found. So that, that's to win either way, right? Yeah, exactly. Well, this is great. And then, and then. So if a, if a patient wants to pursue testing with Palm Health, is that something they need a referral from a doctor

for, can they go on themselves to and sort of self refer. No, no, you, you don't need a referral. It's a self referral. You don't have to convince your primary care doctor to order it for you. That's great. No, no, we actually have a website, it's called palmhealth xyz. And so you just go to that website, you actually can go there and read more about us and about our approach, about all the tests that we utilize and what we look for, of course, the different plans that are available. And then if you are

interested, there's also a wait list if you're still unsure if you. And if you are in states that are not covered yet because, you know, we're slowly covering more and more states because as you know, to be active medically in a state, you need a license. So we're slowly growing that. But we're definitely right now in the major states. In New England we have Massachusetts right now, but we also have New York. We're hoping to go soon into New Jersey. We have Florida, we have Texas, we have California. And

of course we're now focusing on the Midwest as well. So we're slowly growing into different states so that more and more people can join. And unfortunately, because a lot of the people who are interested and reached out to us are in the states that we haven't covered yet. So what some of them have done so far is like they either have friends or family in the states that we have covered. So what they end up doing is they go visit those friends or they stay with the family and, and we have that telehealth

visit from that state. So it's about where you are located rather than where you live. So as long as you travel and talk to us by telehealth from that state that we have covered, we should be fine. But we're hoping to expand more so that people don't really have to do that to talk to us. But we're in the process. We're still growing in the growing phase, so hopefully we'll get there soon. And so on that website, there's a couple of buttons that you can follow. One is for

start screening, which basically goes through the different options that you can go. And then you can create an account, you can look at different plans and different options. You can actually ask questions first or like request callback or send an email and see if you need clarifications on a few things before you commit to anything. And then if you make a choice about how you want to be screened or you want to talk to someone first before you make a choice, that's also possible. And they then

walk you through a list of questions to tell you or basically to know a little bit about your past medical history. And then after you finish that questionnaire, it then takes you to a calendar to pick a date and time that works for you to meet with the oncologist. And then once that day comes, you hop on a call, a telehealth visit basically with the oncologist. We go through your past medical history, you ask all the questions you want, we tell you about what the plan is, what we're planning to do. And then the process is after the call, the oncologist actually

sends a script to a quest lab. So we partnered with Quest Diagnostics, which are all over the country. So we send a script for the labs that we want to use to screen to quest, and then the individual just has to go to their nearest quest lab. It doesn't have to be a specific quest lab. Any lab would have that script. And so they go there, the lab knows what to draw, and then they send it off. And so once the results come back, they come back to us and we post them on the portal. So you'll have

all the results on the portal that you'll have access to if you create an account. And the oncologist will reach out to you again when everything is back, and they will tell you, okay, the results are back. When do you have some time to talk about them and go through them? And then we talk. If everything looks great, there's nothing else to do, if there's something concerning, then we talk about next steps, which could be if it's a very clear cut, like diagnosis that pops up, we know where to go. Like we know, let's say gastric cancer is what we find. So we make the

appropriate connection to make sure you go to an oncologist, either a specialist in gastric cancer or a general oncologist, at least take the next steps or plan for biopsies if there is a mass somewhere, for example, that pops up on imaging and we need to investigate that. But then these things would be done locally. Right? It wouldn't like doing a biopsy. We cannot do that ourselves since this is a telehealth platform. So we would connect you with someone who you can go to in person and do the next steps

for diagnosis. That's great. I applaud you for doing this. This is. This is so needed. And to be able to sort of package all this into one testing program is great because I'm just thinking if someone tried to do all this individually, how many doctor visits would it take to get referrals for each of these tests and orders and try to organize it all and then. And then someone to make sense of all of it. This is great that you package all of it together in a. In one comprehensive testing package. Yeah. Thank you. I mean, that made the most sense. We. I know going through

this is definitely a hard journey to get all of these things together. So packaging or packaging it all in one platform and having done colleges also being part of it is. It's definitely a lot of effort to put all of this together, but I think that would provide the best experience and the smoothest experience to people who want to be screened for cancer. And you said the website again was Palm Health dot xyz? Yep, that's correct. That's P O M Health xyz. Okay, great. I know our listeners will be excited to check that out. Well, Dr. Mouhieddine, anything else

you wanted to cover with us? Anything we didn't touch on that we. You wanted to leave our listeners with? No, I think we. We touched on everything we wanted to actually bring up. And you know, my interest here and my passion about this is really that I want people to know that unfortunately cancer risk and cancer incidence is rising. And we think, while we don't have all explanations to it yet, I think, I personally believe it, eventually we'll see that it has to do with environmental exposures as our world is changing. And

until then, I think what we can do right now is being proactive about detecting things early because we know the risk is now higher and because we have the technologies now, I think that are not so invasive anymore. I think being proactive about things will make a big difference on the long run. I've seen unfortunately firsthand young people going through Stage four cancer, which if they were caught early, we would have. They would be still living their life fully, unfortunately. And for now, the thing that we can

do is this. I'm hoping that this effort will keep growing in the future and not just with us, but from other avenues as well. And as we show in the future that this is helping people and saving lives, I think it'll become more and more accessible. It'll be covered. I really hope so. Because what. Even though this is great and makes me happy that we are doing this effort and actually screening and making sure people are in good shape, it still frustrates me and makes me sad

that it's also not so accessible. If I wish this, we could get this done fully covered for everyone by insurance or by Medicare or Medicaid, but we're not there yet. But I'm hoping that at some point in the future that will be the case so that everybody gets equitable access to all of this. Really good. And I believe eventually life saving technology. Yeah, I believe we'll get there too. And you know, because everyone, everyone deserves to have. This is, is honestly part of their standard of care in terms of

just preventive maintenance and wellness visits. Right. I mean, this should be part of it. Yeah. Just as we screen for heart disease and diabetes, we should be screening for cancer to this level as well. So. Yeah, yeah, I completely agree. And while not everyone is still on, on that same page, I think more and more doctors are beginning to really see the benefit and the advantage of having this. And I think it's a matter of time before we have more and more proof even that this is how things should be done and this is how

the world is going to change into. It's about more being proactive and screening early so that we avoid the long term side effects and the long term consequences, if you can call it consequences, but like avoiding basically stage four. Living in a world where stage one is the late or the most advanced cancer that we get to. I love that goal. Let's do it. Let's do it. Yeah. Well, Dr. Mouhieddine, thank you again for your time today. I know you're a busy guy and

you've got a lot going on and really, really honored that you chose to spend some time with us today. No, it was, it was a pleasure and an honor for me as well. Thank you so much for having me on your program and I look forward to connecting with you again in the future. And for all your listeners, you know, like I mentioned, if they want to know more, they can go to the website and of course they can request a call as well if they needed more clarifications about things. So some of, some of the people who have created accounts and we've met through Palm Health, actually sometimes they before

they made that commitment they actually started with a clarification call like they wanted to better understand a few things. So I highly encourage people to do that as well if they're not 100% sure about what to do. Okay, sounds great. Well, thank you again. And again that's palmhealth xyz. I encourage our listeners to check that out. We're interested in really doing the, the, the finest screening that we have available today. So but thank you again. And just a reminder to our listeners, you know, we have many, many more great episodes coming your way in this season, in future seasons. But thank you again for joining us. And until next time,

bye bye. Goodbye.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. CSP S7E100 - Ep.100, 100 Episodes of Cancer Secrets: Lessons in Hope, Science, and Self-Advocacy

    Nov 10, 20268 minAudio

    What do 100 episodes of conversations, research, and patient stories teach us about cancer care? In this milestone episode, Dr. Jonathan Stegall reflects on how the podcast has shaped his approach to integrative...

    Credit the people on this episode

  2. CSP S7EO99 - Ep.99, Caregiver Burnout: Strategies for Support and Hope in the Cancer Journey

    Sep 23, 20268 minAudio

    In this insightful episode of the Cancer Secrets Podcast, Dr. Jonathan Stegall shifts the spotlight to an often-overlooked group in the cancer journey: caregivers. He explores the heavy toll caregiving takes, discussing...

    Credit the people on this episode

  3. CSP S7EO98 - Ep.98, Unlocking the Microbiome: How Gut Health Impacts Cancer Risk, Treatment, and Recovery

    Aug 18, 20269 minAudio

    In this episode of the Cancer Secrets Podcast, Dr. Jonathan Stegall dives into the critical but often overlooked role of the gut microbiome in cancer care. He explains how nearly 70% of the immune system resides in the...

    Credit the people on this episode

  4. CSP S7EO97 - Ep.97, Integrative Oncology Meets Longevity Medicine: Practical Steps for Cancer Survivors

    Jul 17, 202630 minAudio

    In this enlightening episode of the Cancer Secrets podcast, Dr. Jonathan Stegall dives deeper into the intersection of longevity medicine and integrative oncology. Building on the foundations laid in the previous...

    Credit the people on this episode

  5. CSP S7EO96 - Ep.96, How Longevity Medicine and Integrative Oncology Are Connected

    Jun 16, 202618 minAudio

    In this insightful episode of the Cancer Secrets podcast, Dr. Jonathan Stegall bridges the worlds of longevity medicine and integrative oncology. He explores the fascinating overlap between aging and cancer, revealing...

    Credit the people on this episode